ALLOGENEIC BONE MARROW TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY

异体骨髓移植治疗血液恶性肿瘤

• 批准号: 6102092
• 负责人: Stephen J Forman
• 金额: $ 22.99万
• 依托单位: CITY OF HOPE NATIONAL MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-02-01 至 2000-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6102092
• 关键词: acute lymphocytic leukemia; amphotericin B; antifungal agents; bone marrow transplantation; cell mediated lymphocytolysis test; clinical trials; cyclosporines; cytomegalovirus; disease /disorder prevention /control; ganciclovir; graft versus host disease; homologous transplantation; human subject; human therapy evaluation; methotrexate; mycosis; neoplasm /cancer therapy; polymerase chain reaction; serology /serodiagnosis; urinalysis; viral vaccines

The goal of our studies is to achieve further progress in the areas of allogeneic transplantation which would result in improved disease free survival and cure rates by a) Decreasing the leukemia relapse rate following marrow grafting; b) Reducing the incidence of acute and chronic graft-versus-host disease; c) Preventing the development of CMV associated interstitial pneumonia; and d) Decreasing the complications of the preparatory regimen. To this end we propose five clinical trials in this project entitled "Allogeneic Bone Marrow Transplantation for Hematologic Malignancy". We propose to conduct a series of Phase I, II and III trials designed to improve the efficacy and reduce the toxicity of the preparatory regimen used for patients undergoing allogeneic marrow transplantation. In addition, we will continue and extend our trials in the chemoprophylaxis of acute graft-versus-host disease after both related and unrelated bone marrow transplantation. We will also conduct trials to address the infectious complications of marrow transplantation by improving the prophylaxis of cytomegalovirus infection utilizing either pharmacologic or immunologic methods and we will explore novel approaches to the prevention of fungus infection after marrow transplantation. Four of the five specific aims will be carried out jointly at the City of Hope National Medical Center and at Stanford University. In the past, these two institutions have collaborated closely in clinical trials which have yielded promising results. The hypothesis to be tested is that the regimens described in this proposal may lead to results which are superior to those obtained with other widely utilized approaches and will increase the safety of the therapy. We have proposed prospective trials to define the role of new regimens used to ablate leukemia and prevent graft-versus- host disease and infection that have been developed from research performed by the investigators in this Program Project Grant.

我们研究的目标是在以下领域取得进一步进展： 同种异体移植，这将导致改善无病 a）降低白血病复发率 B）减少急性和慢性骨髓移植的发生率， c）预防CMV相关性疾病的发生; 间质性肺炎;以及d）减少 预备方案。 为此，我们提出了五项临床试验， 名为“同种异体骨髓移植治疗血液病”的项目 “你好”。 我们建议进行一系列第一、第二和第三阶段试验， 提高疗效，降低预处理方案的毒性 用于异基因骨髓移植患者。 在 此外，我们将继续并扩大我们在化学预防方面的试验， 急性移植物抗宿主病相关和无关骨 骨髓移植 我们亦会进行试验， 骨髓移植感染并发症的治疗 利用药物或免疫抑制剂预防巨细胞病毒感染 我们将探索新的预防方法， 骨髓移植后的真菌感染 其中四 具体目标将在国家希望之城联合实施， 医学中心和斯坦福大学。 在过去，这两个 各机构在临床试验中密切合作， 取得了可喜的成果。 要检验的假设是， 本建议中描述的方案可能导致上级的结果 与其他广泛使用的方法获得的结果相比， 治疗的安全性。 我们已经提出了前瞻性试验来定义 用于消融白血病和预防移植物抗肿瘤的新方案的作用 研究中发现的宿主疾病和感染 由本项目资助的研究人员进行。